PLG0206 for Joint Infections

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Joint InfectionsPLG0206 - Drug
Eligibility
18 - 79
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying the safety and efficacy of PLG0206 in treating patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) using the DAIR surgical procedure.

Eligible Conditions
  • Joint Infections

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: approximately 1 year

approximately 1 year
The percentage of treatment emergent AEs

Trial Safety

Trial Design

2 Treatment Groups

3 mg/mL PLG0206
1 of 2
10 mg/mL PLG0206
1 of 2

Experimental Treatment

14 Total Participants · 2 Treatment Groups

Primary Treatment: PLG0206 · No Placebo Group · Phase 1

3 mg/mL PLG0206
Drug
Experimental Group · 1 Intervention: PLG0206 · Intervention Types: Drug
10 mg/mL PLG0206
Drug
Experimental Group · 1 Intervention: PLG0206 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 1 year

Who is running the clinical trial?

Wellcome TrustOTHER
199 Previous Clinical Trials
15,629,607 Total Patients Enrolled
Department of Health and Human ServicesFED
201 Previous Clinical Trials
468,686 Total Patients Enrolled
PeptilogicsLead Sponsor

Eligibility Criteria

Age 18 - 79 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a pre- or intra-operative diagnosis of TKA-PJI.